IGC Pharma (IGC) Liabilities and Shareholders Equity (2011 - 2026)

IGC Pharma (IGC) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $9.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.01% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $36.6 million (down 5.68% YoY), while the FY2026 annual figure was $9.2 million, up 5.01% from the prior year.
• Liabilities and Shareholders Equity slipped to $9.2 million in Q1 2026 per IGC's latest filing, from $9.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $26.8 million in Q1 2022 and bottomed at $7.9 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $14.1 million across 5 years, with a median of $10.6 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 43.9% — and 2025, when it gained 6.98%.
• IGC Pharma's Liabilities and Shareholders Equity stood at $20.1 million in 2022, then slumped by 43.9% to $11.3 million in 2023, then fell by 19.37% to $9.1 million in 2024, then climbed by 6.98% to $9.7 million in 2025, then decreased by 5.43% to $9.2 million in 2026.
• Business Quant data shows IGC's Liabilities and Shareholders Equity at $9.2 million in Q1 2026, $9.7 million in Q4 2025, and $9.7 million in Q3 2025.